Drug Trial Radar · NCT02286921
Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance
Last checked: Nov 20, 2026Latest source record: Nov 6, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
222
Actual
Start
Jan 2015
Primary completion
Oct 26, 2018
Study completion Feb 21, 2020
Sponsor
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- United States Department of Defense
- First posted
- Nov 10, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Male only, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Asymptomatic men with progressive metastatic Castration-resistant prostate cancer (CRPC) post- treatment with abiraterone acetate (pre-chemotherapy for metastatic disease) will be treated on a randomized, multi-Institutional open label study to determine if treatment with intramuscular T given on a dose/schedule designed to result in rapid cycling from the polar extremes of supraphysiologic to near castrate levels \[i.e. Bipolar Androgen Therapy (BAT)\] will improve primary and secondary objectives vs. enzalutamide as standard therapy.
Conditions
- Castration Resistant Metastatic Prostate Cancer
Interventions
Testosterone cypionateDrug
Depo-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. Depo-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.
EnzalutamideDrug
Enzalutamide is a white crystalline non-hygroscopic solid. It is practically insoluble in water. Enzalutamide is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides. The inactive ingredients are caprylocaproyl polyoxylglycerides, butylated hydroxyanisole, butylated hydroxytoluene, gelatin, sorbitol sorbitan solution, glycerin, purified water, titanium dioxide, and black iron oxide.
Testosterone EnanthateDrug
Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival as Measured by Number of Months Until Clinical or Radiographic ProgressionTime frame: up to 2 years
Locations
17 sites in 1 country. Site status is shown where the registry gives one.
Unversity of Alabama
Birmingham, Alabama
City of Hope
Duarte, California
University of Colorado Cancer Center
Aurora, Colorado
Sibley Memorial Hospital
Washington D.C., District of Columbia
Piedmont Cancer Institute
Atlanta, Georgia
University of Chicago
Chicago, Illinois
University of Kansas Cancer Center
Kansas City, Kansas
Tulane University Medical Center
New Orleans, Louisiana
University of Maryland
Baltimore, Maryland
SKCCC at Johns Hopkins
Baltimore, Maryland
University of Michigan
Ann Arbor, Michigan
Neraska Cancer Specialists
Omaha, Nebraska
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey
Cleveland Clinic
Cleveland, Ohio
Allegheny Health Network
Pittsburgh, Pennsylvania
Huntsman Cancer Institute
Salt Lake City, Utah
University of Washing
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.